

## REVIEW ARTICLE

# Neurobiological Investigation of Depression: Unraveling the Biological Basis of a Complex Mental Health Challenge

Archana Panigrahy\*<sup>1</sup>, Shakti Ketan Prusty<sup>1</sup>, Ghanshyam Panigrahi<sup>2</sup>

<sup>1</sup>*Department of Pharmacology, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar, Odisha, India.*

<sup>2</sup>*Department of Pharmacology, Royal College of Pharmacy and Health Sciences, Berhampur, Odisha, India.*

*Received: 22<sup>nd</sup> September, 2023; Revised: 27<sup>th</sup> October, 2023; Accepted: 15<sup>th</sup> November, 2023; Available Online: 25<sup>th</sup> December, 2023*

---

## ABSTRACT

Individual depressive theories founded on neurobiological information are examined because they hold great relevance to both clinical investigators seeking to create innovative treatments for depression and physicians in everyday practice. One such theory is the proposition that the main underlying issue behind depressive disorders is a deficiency in central monoaminergic function. This theory highlights the importance of addressing the role of neurotransmitters such as glutamate, gamma-aminobutyric acid (GABA), norepinephrine, serotonin, and dopamine, as well as factors like neurocircuitry, neurotrophic factors, and the rhythm of the circadian clock. Major depressive disorder, a severe condition with significant societal and therapeutic implications, necessitates tailored antidepressant treatments. These treatments encompass both pharmacological interventions and emotional therapies, all of which need to be customized based on specific patients and medical circumstances. The understanding of depression is complex and constantly evolving, with various explanations and theories applying only to specific types of depressed individuals while disregarding others. Furthermore, the pathogenesis of depression can undergo significant changes during the disease's development. This dynamic nature challenges the notion that depression can be characterized by a single hypothesis or theory. Thus, the extensive body of available research highlights the need for a comprehensive approach that incorporates multiple concepts and factors when studying and treating depression. By considering the intricate interplay of various neurobiological elements and personal circumstances, researchers and medical professionals can strive to provide more effective and tailored interventions for individuals suffering from depression.

**Keywords:** Depression, Theory, Factors, Mechanism, Biological Action

International Journal of Pharmaceutical Quality Assurance (2023); DOI: 10.25258/ijpqa.14.4.71

**How to cite this article:** Panigrahy A, Prusty SK, Panigrahi G. Neurobiological Investigation of Depression: Unraveling the Biological Basis of a Complex Mental Health Challenge. International Journal of Pharmaceutical Quality Assurance. 2023;14(4):1287-1295.

**Source of support:** Nil.

**Conflict of interest:** None

---

## INTRODUCTION

According to the World Health Organization's (WHO's) projections, depression will have a significant impact on global morbidity in the next decade, ranking second after cardiovascular diseases. This mental health disorder is expected to affect one in five women and twelve men, causing immense suffering and hindering their ability to lead fulfilling lives.<sup>1</sup> It is crucial to note that depression does not discriminate based on age; research shows that 2% of school-age children and 5% of teenagers also suffer from this condition. Shockingly, most cases of depression go undetected, making it a silent epidemic with far-reaching consequences. Despite the growing awareness about mental health, there still exists a widespread misconception about depression. Many people believe that it is simply a personality defect or a sign of weakness, leading

to stigma and discrimination against those who are struggling with this illness. Another myth surrounding depression is that it can be healed through self-care alone without seeking professional help. However, the truth is that depression is a complex disorder with various contributing factors, and treatment often requires therapeutic interventions. Moreover, while some may view antidepressant medication as a quick fix for depression, the reality is quite different. Prescription drugs are not sedatives but rather potent medications that can effectively alleviate symptoms and improve an individual's overall well-being when used correctly under the guidance of a psychiatrist. It is essential to debunk these myths about depression and understand its true nature as a legitimate mental health disorder with scientifically proven treatments available. Seeking help from mental health professionals should

---

\*Author for Correspondence: [archanapanigrahyroyal@gmail.com](mailto:archanapanigrahyroyal@gmail.com)

be encouraged and normalized instead of stigmatized. With proper support and treatment, individuals struggling with depression can lead healthy and fulfilling lives. They are all myths, the majority of which were spread for their benefit by individuals who were ignorant of society, religious healers, inexperienced counselors, and non-medical experts. More awareness of and respect for psychiatrists has been the main driver of the increase in patients, not necessarily an increase in prevalence. Depression therapy has become easier with the advancement of facilities and medications. Most patients respond to therapy well and return to their pre-treatment level of performance somewhat quickly.<sup>1,2</sup>


As shown in Figure 1 varieties of depressive disorders: Like many other disorders, depression may take many distinct forms:

- Major depression is a complex mental disorder characterized by a range of symptoms that can have a profound impact on an individual's ability to function. These symptoms may include difficulties with work, sleep, appetite, and participation in previously enjoyable activities. To be diagnosed with major depression, an individual must experience these impairments for an extended period and across various settings. Such incapacitating depressive episodes are not uncommon and can occur at any point in one's career, recurring once, twice, or even multiple times throughout their lifetime. This debilitating condition requires proper diagnosis and treatment to manage the symptoms and improve overall functioning.
- Dysthymia, a mental health disorder, is considered to be a less severe form of depression that is characterized by ongoing and persistent symptoms that interfere with one's daily life and prevent them from functioning at their optimal level. Those who suffer from dysthymia may have difficulty feeling good or fully engaging in activities due to the chronic nature of their symptoms. Additionally, individuals with dysthymia may also experience major depressive episodes on occasion, adding to the complexity of the disorder.
- Bipolar disorder or manic-depressive disease are less common than other types of depression. Cycles of mania or euphoria and depression are involved. Though they usually happen gradually, mood shifts can occasionally be dramatic and swift. A person experiencing a depressive episode may exhibit any or all of the following symptoms. Any or all of the mania symptoms may be felt during the manic phase. Psychosis frequently harms reasoning, decision-making, and social conduct, which can lead to significant issues and humiliation.<sup>1-5</sup>

As shown in Figure 2 Signs and symptoms of depression may include the following:

#### **Persistent Depressive Symptoms**

People going through a depressive episode may feel a generalized sensation of hopelessness, emptiness, or unhappiness that doesn't seem to go away. They may have a sense of emptiness and hopelessness as a result of this mental condition.



**Figure 1:** Exploring the different types of depression

#### **Loss of Interest in or Enjoyment from Activities**

A typical sign of depression is a discernible decrease in interest in or enjoyment from once-pleasurable activities. A feeling of alienation and retreat can be exacerbated by hobbies, socializing, and even routine daily responsibilities that become tedious and unpleasant.

#### **Appetite or Weight Changes**

A person's appetite and weight might frequently alter significantly during depressive episodes. Some people may lose weight due to a decrease in hunger, and those who gain weight due to an increase in appetite. Their general well-being and sense of self-worth may be further impacted by these swings.

#### **Sleep Disturbances**

When depressed, insomnia and excessive sleeping are common symptoms. Some people could have trouble falling asleep, and have restless nights and never-ending thoughts, while some people might sleep a lot but wake up feeling exhausted. These disruptions may make tiredness worse and have an impact on daily activities.

#### **Fatigue or Lack of Energy**

People who are depressed frequently talk about how they are always exhausted and lacking in energy. Even simple chores that were formerly possible could seem difficult and need a lot of work. This ongoing tiredness can damage interpersonal relationships and impair productivity.

#### **Difficulty Focusing or Making Decisions**

Depression episodes frequently cause cognitive deficits. Individuals may find it difficult to stay focused, suffer from memory lapses, and find it difficult to make even basic judgments. These challenges can be stressful and upsetting for the person and harm employment or academic performance.

#### **Feelings of Excessive Guilt or Worthlessness**

People who are depressed may have low self-esteem and a skewed view of their value. They might obsess about previous transgressions or experience intense remorse for events that were out of their control. These unfavorable opinions about oneself have the potential to prolong the depressive cycle and impede recovery.

#### **Persistent Thoughts of Suicide or Death**

People who are going through severe depressive episodes may find themselves thinking about suicide or death frequently.



**Figure 2:** Understanding the various symptoms that can occur during depressive episodes

Always take these ideas seriously, and get in touch with a healthcare provider right away. It's critical to provide support and get the right assistance for anyone experiencing these kinds of upsetting thoughts.

Understanding the various symptoms that can occur during depressive episodes is important for recognizing and addressing the condition. If you or someone you know is experiencing prolonged and distressing symptoms of depression, it is recommended to consult a healthcare provider for a proper diagnosis and treatment plan. Remember, seeking support and professional help is essential in overcoming depression and improving overall well-being.

### Stress and Depression: Uncovering the Biological Mechanisms

Due to the medical and etiological heterogeneity in important depressive disorders, such has been challenging to explain the neurobiological factors a term used to describe how something works. The advantages and disadvantages of current neurobiological theories with a solid scientific basis or the best therapeutic utility are assessed.<sup>1</sup>

A cohesive conception of melancholy is discouraged by the present state of research because comprehensive ideas about depression depend on only a small subset of depressed patients and not on other people, and because the reasons for depressive symptoms can vary greatly throughout the illness.

### The Role of Serotonin Messenger in Major Depressive Illness: A Genetic Perspective

Studies on family, binary, and relinquishment provide provably robust and consistent evidence that severe depressive illness runs in families and that this familiarity is mostly due to genetic reasons that may be passed down via generations.<sup>1</sup> The significance of the mother's social behavior and other residential psychosocial stressors in the development of major depressive illness is demonstrated by this important finding, which suggests that treatment shouldn't be focused primarily on them. Genetic factors account for 30 to 40% of the variation.<sup>2</sup> Excess 60 to 70% of the variation in vulnerability to major depressive

disorder can be explained by non-genetic factors, specifically independent-explicit environmental effects (including estimation error impacts and the quality climate between activities). These effects are typically negative events that occur during childhood and ongoing or ongoing stress brought on by relationship difficulties, such as childhood sexual abuse, other permanent injuries, a lack of supportive relationships, marital issues, and divorce. These outcomes propose that there is enormous potential in the avoidance of major depressive disorder additionally, these outcomes represent the clinical act of precisely validated psychotherapy techniques for the treatment of depression. Interventions in psychological disorders (e.g., in education, at the office)<sup>3</sup>, including relational, psychodynamic, and mental social psychotherapies and mental behavioral examination arrangement of psychotherapy, which all center straightforwardly or by implication around relational challenges and abilities. This does not exclude the possibility that unexplained non-psychosocial, non-hereditary risk factors might also play a major role in some individuals, such as clinical conditions or climate change. A stress response is seen in a halfway orientation in the shadows. While going through challenging times in life can be depressing for both men and women, the type of stressor might affect how each person responds. Men are prone to distressing periods following separation, division, what's more, work challenges, though ladies are touchier to occasions in their proximal interpersonal organization, for example, trouble getting alongside an individual, difficult disease, or on the other hand demise.<sup>4</sup> These discoveries highlight the significance of orientation touchy psychosocial methodologies in the avoidance and treatment of major depressive disorder. There is no compelling evidence supporting the involvement of explicit qualities and explicit quality by-climate partnerships in the pathophysiology of major depressive illness, in contrast to the very strong evidence from epidemiological research on broad hazard factor domains. Studies of genome-wide association have shown that a multitude of traits with minimal bearing on complicated disorders are implicated, making it more difficult to discern between these traits.<sup>4</sup> While there has been progress in the quest for hazard qualities for a very long time plex sicknesses regardless of this methodological issue<sup>5</sup>, mental circumstances have ended up being extremely impervious to hearty quality distinguishing proof. for example, a prospective study based on a local area has indicated that the pathophysiology of depression may include a genetic difference in the serotonin messenger's regulatory regions (a focus of energizer drugs).<sup>6</sup> A recent meta-analysis showed no evidence linking serotonin carrier quality, either alone or in conjunction with mental load, to the risk of depression, despite the message's strong clinical and neurobiological plausibility.<sup>7</sup> The low effectiveness of hereditary evaluations of sorrow has been associated with the use of current-order mappings, such as ICD-10 and DSM-IV. Rather than portraying uniform problems, these diagnostic guidelines are based on clusters of symptoms and clinical traits that indicate the typical outcomes of several pathophysiological processes.<sup>8</sup> The therapist should be informed that the best



source of information for figuring out the genetic risk of major depressive illness will always be one's family history.

### **Exploring the Hypothalamic-pituitary-adrenal Axis (HPA) Dysfunction in Depression**


When parts of the cortical cerebrum sense psycho-legitimate stress, the nerve center releases corticotropin-releasing hormone (CRH). This substance stimulates the pituitary gland to release cortisol into the plasma, activating the adrenal gland. Males and women have different levels of major pressure reactivity, which is consistent with the fact that males suffer less profound sadness than women. The physiologic stress reaction is a component of the way orientation manifests.<sup>9</sup> Men also respond to challenges with achievement with greater cortisol levels, whilst women are more sensitive to issues with public humiliation.<sup>10</sup> Even though major depressive disorder is considered a stress condition, many people with the illness show no signs of hypothalamic-pituitary-adrenal (HPA) abnormalities.<sup>11</sup> Regardless, some major depressive disorder patients do exhibit aberrations in that pivot as well as the extrahypothalamic CRH framework.<sup>12</sup> Patients with a history of developmental trauma who were distressed tended to have more noticeable alterations in their stress hormone production.<sup>13</sup> Significant melancholy may have long-term negative effects on one's health, including coronary artery disease, type II diabetes, and fractures, which may be mediated by high cortisol levels.<sup>14</sup> The significance of hypothalamic pituitary adrenal pathway malfunction for antidepressant viability is a matter of conversation.<sup>15</sup> A twofold arrangement of mineralocorticoid (MR) and glucocorticoid (GR) receptors regulates this HPA pivot. In stress-related situations like MDD, decreased brain GR receptor work<sup>16</sup>, and increased MR framework action capacity suggest an uncomfortable MR/GR proportion.<sup>17</sup> The glucocorticoid receptor regulatory guideline has been linked to adolescent abuse.<sup>18</sup> Such environmental programming of quality articulation may address one potential component that joins early life stress to unusual HPA pivot work and expanded gamble of MDD in grown-ups. Although the central brain corticotropin-releasing hormone excitement test is sensitive to hypothalamic-pituitary-adrenal axis disruption in depression, it has limited specificity for serious depressive disorder.<sup>19</sup> In any event, failure to disclose in the CRH test has repeatedly shown a higher probability of serious backsliding following treatment lowering. Additionally, an awake salivary cortisol fixation estimate is a quick and accurate way to detect HPA hub hyperactivity in depressive states.<sup>20</sup> Only insanelly sad people get hypercortisolemia, which glucocorticoid antagonists may be able to treat.<sup>21</sup> Several types of evidence suggest that CRH is important in the pathophysiology of several kinds of depression. CRH levels in the cerebral fluid are higher in a small number of discouraged persons.<sup>22</sup> Posthumous research found more CRH-producing neurons in limbic regions of the brain in miserable people, possibly reflecting a protective response to the elevated CRH concentrations.<sup>23</sup> What's more, reduced appetite, irregular sleep patterns, a reduction in physical attractiveness, and changes in cognitive

content are just a few of the physiological and social changes caused by CRH that resemble the signs of serious depression. Additionally, preliminary data suggests that CRH1 receptor antagonists reduce feelings of anxiety and depression.<sup>24</sup> As a result of the inflammatory reaction system activation, "sick behavior" symptoms include fatigue, feelings of hopelessness, psychomotor slowness, and cognitive impairment. Pro-inflammatory cytokines that disrupt the central serotonin system and stimulation of the HPA axis include growth mortification, interleukin-6, and interleukin-1. One of the most frequent side effects of recombinant interferons is depression, which predominates for 30 minutes.<sup>25</sup> Inhibiting the signaling mediated by pro-inflammatory cytokines in animals has effects akin to antidepressants. Clinical data points to the potential involvement of cytokines in the etiology of certain depression, especially in somatically disturbed individuals. A possible therapeutic relationship between neurobiology and clinical depression analysis may be revealed by the painkiller's medicinal qualities.<sup>26</sup> When taken as a whole, laboratory tests that support systemic imbalances and neuroimmune complexes have the highest likelihood of being clinically helpful in the treatment of depressed persons. The outcomes of utilizing medication to control the hypothalamic-pituitary-adrenal axis as an antidepressant have not been satisfying due to a considerable amount of fundamental scientific data showing that this system plays a significant part in the pathophysiology of depression. Owing to the stress system the relationship between childhood trauma and a body that has changed, for better or worse certain psychotherapies are utilized in the treatment of depressive individuals who have experienced early-life trauma.<sup>27</sup>

### **Exploring the Relationship Between Monoaminergic Systems and Brain Function**

The bulk of the serotonergic, noradrenergic, and dopaminergic neurons that send signals to important areas of the brain are found in the mesencephalon and neural structural nuclei. The monoaminergic systems are suggested by this physiology. Square measure concerned with the control of a wide range of brain functions, together with motivation, emotion, and attention process, sleep, hunger, and cognition are all factors to consider. Almost any substance that inhibits amine reuptake, leads to associate multiplied the presence of monoamine in the connection gap has been demonstrated to be a therapeutically effective antidepressant.<sup>28</sup>

provide the strongest evidence for significantly diminished central serotonergic system function. In individuals who are prone to depression, such as those with completely recovered major depressive disorder or healthy persons with a family history of depression, such a discount triggers the emergence of depressive symptoms.<sup>29</sup> This might be mediated by an increase in brain metabolism in the reticular formation anterior cortex and parts of the neurological framework of the brain. A reduction in central 5-hydroxytryptamine has been linked in clinical evidence to psychological memory bias, changed reward-related behavior, and disturbance



**MAO-A:** monoamine oxidase inhibitor, **CREB:** cAMP-response element binding protein, **PKC:** protein kinase C, **SERT:** serotonin transporter, **NET:** norepinephrine transporter, **IP3** **DAG:** inositol trisphosphate, and diacylglycerol

**Figure 3:** Depression Mechanism by Neurological Framework

in suppressing emotional processes. These findings lend credence to the serotonin insufficiency theory. Moreover, there is proof that the 5-hydroxytryptamine receptor is altered in depressive disorders; the majority of this data indicates that the serotonin 1A receptor, which regulates the 5-hydroxytryptamine receptor's activity, is responsible for these modifications. This anomaly has been seen in individuals with anxiety disorders and temporal lobe brain disease, albeit it is not particularly unique to major depressive disorder. This may help to explain the substantial comorbidity of these illnesses.<sup>30</sup> There is no clear reason for how sad people lose serotonin, and investigations of monoamine neurotransmitter metabolites in plasma, feces, and body fluid, as well as post-mortem examinations of the serotonergic system in sadness, have produced contradictory findings. According to early research, AN increased the accessibility of a brain enzyme that metabolizes monoamine neurotransmitters, which may result in a serotonin deficit.<sup>31</sup> The lack of function mutations in the sequence promising to write for the brain-specific accelerator tryptophane hydroxylase-2 might further justify serotonin production loss as an uncommon cause of depression.<sup>32</sup> Evidence from depressed patients of decreased monoamine neurotransmitter metabolism increased amino acid hydroxylase activity, and exfoliated density of norepinephrine transporter within the reticular formation supports the theory that central noradrenergic system dysfunction contributes to the pathophysiology of major depressive disorder.<sup>33</sup> Depressive disorders attempters' retrospective brain analyses showed reduced locus changes, increased alpha-2 adrenergic receptor frequency, and catabolized alpha-1 adrenergic receptor density in their brains.<sup>34</sup> Since there is no way to selectively eliminate central norepinephrine or imaging technology to look at the central monoamine neurotransmitter system, there is a lack of solid evidence confirming the central monoamine neurotransmitter system's involvement in depression. Although monoamine neurotransmitters have been a major focus of classic ideas of depression neurobiology, intropin's role in depression is receiving more and more

attention.<sup>35</sup> In investigations into having major depressive disorder that were placebo-controlled, Intropin reuptake inhibitors (like nomifensine) and dopamine receptor agonists (like pramipexole) demonstrated therapeutic efficacy.<sup>36</sup> In depression, levels of Intropin metabolites in body fluid and venaplasma were consistently reduced, indicating that target surface Intropin turnover occurs. Major depressive disorder reduces Striatal Intropin transporter binding and dopamine uptake, resulting in decreased dopamine neurotransmission.<sup>37</sup> According to one study, reduced dopaminergic transmission into the forebrain relates to physiological feelings and performance deficiencies on an appreciation procedure test in those at risk of depression.<sup>38</sup> These findings support the clinical observation that depressed persons respond slowly to praise and inconsistently to criticism. Nearly all antidepressants that target the amine systems are available.<sup>39</sup> The dysfunctions of the monoaminergic neurochemical system characterized by major depressive illness are after other, more severe issues, as evidenced by the complete and partial resistance to such medications as well as their prolonged onset of action. Despite this weakness, the monoamine shortage theory has been the most prominent target tissue explanation of stress. Though current studies on the impact of hormones associated with stress in depressive crises emphasize the theory's academic prospects, promising indicates of the antidepressant effects of drugs that directly influence the dopaminergic system (e.g., pramipexole, modafinil) in difficult-to-treat depressive disorders emphasize the theory's clinical importance.<sup>40</sup>

### The Intriguing Connection Between Neuroimaging and Treatment-resistant Depression

Despite the failure of various historical initiatives to localize mental functions, they have made a substantial contribution to contemporary neuroscientific knowledge about mental diseases.<sup>41</sup> Researching structural and functional deficits in depressed people who are still alive is now possible because of advancements in neuroimaging technologies. Sadly, Because of the wide range of imaging modalities used, the small and diverse research groups investigated, and the limited data overlap across neuroimaging conceptual frameworks. Neural networks or areas with persistently aberrant structure or function in severe depressive disorder are hard to reliably identify. Research on brain imaging for functional purposes has produced the least amount of information. This could lead to poor process quality and/or methodological limitations in depression disorders. The lateral frontal and temporal cortices, striatum, and cerebellum exhibit the most convincing evidence of abnormal brain activity in depression disorders, according to a recent metanalytic analysis. These regions of the brain exhibited sporadic activity while at rest, no reaction when unpleasant thoughts were presented, and increased activity following treatment with monoamine neurotransmitter reuptake inhibitors. In the ventromedial frontal areas, the striatum, and maybe alternative neural structure brain regions, opposite modifications may arise.<sup>42</sup> Postmortem examinations and molecular imaging have added

to the evidence. The left anterior orbital and orbitofrontal cortex, as well as the ventromedial prefrontal cortex, all showed abnormally high-volume declines, according to a new meta-analysis of brain volume anomalies in major depressive disorder. Mild volume decreases were seen in the basal ganglia, hippocampus, and lateral anterior cortex. After autopsies, the corpus amygdaloideum, as well as the dorsal, orbital, and subgenual anterior cortices, showed reduced interstitial tissue cell count.<sup>43</sup> The most frequent anatomical outcome of severe depressive illness, according to functional, structural, and post-mortem investigations, is structural and functional abnormalities in the left subgenual cingulate cortex region. Volume reduction in this region was detected early in the course of the illness, and young people with a high familial risk of MDD were studied,<sup>44</sup> referring to a major biological science abnormality linked to the pathophysiology of the illness. Humans with subgenual anterior cortical lesions displayed aberrant involuntary reactions to social stimuli,<sup>45</sup> whereas animals suffering from left-sided injuries showed increased sympathetic arousal and glucocorticoid sensitivity in response to restraint stress. In persons suffering from treatment-resistant depression, continuous deep brain stimulation to diminish possibly elevated activity in the subgenual cingulate cortex had therapeutic outcomes.<sup>46</sup> In conclusion, despite the wide range of neuropsychological study findings, an increasing body of information suggests that some patients with severe depressive disorder have irregularities in the subgenual anterior brain. Studies on depression using neuroanatomy are highly clinically relevant because new medications for depression, like deep brain stimulation, will target specific brain regions. Additionally, studies using neuroimaging can evaluate the potential for treatment responses.<sup>47</sup>

### How Untreated Depression Exacerbates Stress Sensitivity

As the illness worsens, so do the risk factors for depressive episodes.<sup>48</sup> However, future episodes grow progressively “endogenous,” meaning they are triggered by little stressors or occur on their own. The initial stage of depression is occasionally “reactive,” meaning it is brought on by significant psychosocial stresses.<sup>49</sup> There is strong proof that the extent and duration of depression are associated with reductions in hippocampal volume and other brain regions.<sup>50</sup> This suggests that if depression remains untreated, the loss of hippocampal volume will exacerbate stress sensitivity and increase the likelihood of relapse.<sup>51</sup> Decreased neurotrophic factors, delayed maturation, glutamatergic toxicity,<sup>52</sup> glucocorticoid neurotoxicity, and reduced neurotrophic factors are some possible causes of depression-induced brain volume reduction.<sup>53</sup> There is inadequate proof for any of these pathways because there are no imaging methods to accurately evaluate neurotoxic and neurotrophic processes in vivo. BDNF, or brain-derived neurotrophic factor, has sparked a lot of curiosity.<sup>54</sup> Diagnostic investigations have found links between stress-induced depressive-like behavior and lower BDNF levels in the hippocampus, as well as higher BDNF expression after drug treatment.<sup>55</sup> Depression is a potential side effect that might

harm the brain; consequently, depressed patients should be treated as soon as possible.<sup>56</sup>

### GABAergic Exploring the Link Between Emotional Stress and Presynaptic Down-regulation of GABAergic Neurotransmission

Gamma-aminobutyric acid (GABA) average concentrations in the brain and skeletal locations are lower in acute depressive disorders, according to a series of magnetic resonance spectroscopy studies.<sup>51</sup> Presynaptic down-regulation of anterior GABAergic neurotransmission appears to be a consequence of emotional stress, and this may replicate the consequences of acute stress. Low total neurotransmitter concentrations, on the other hand, may result in a decrease in GABAergic interneuron density and size.<sup>57</sup> Chronic stress may also alter GABA-A receptor activation, most likely as a result of alterations in the manufacture of neuroactive steroids.<sup>58</sup> GABAergic medications have little impact on core depressive symptoms<sup>59</sup> and conventional anterior neurotransmitter levels in persons with remitted MDD provide contradictory evidence for the neurotransmitter model of depression.<sup>60</sup> Numerous pieces of research suggest that depression problems are associated with a dysfunctional sodium neurotransmitter pathway.<sup>61</sup> A single dosage of the sodium N-methyl-D-aspartate (NMDA) receptor antagonist club drug showed notable and rapid beneficial effects in patients with depression who are resistant to treatment disorders.<sup>62</sup> Salt unharnesses inhibitors, for example, lamotrigine and riluzole, clearly have antidepressant characteristics;<sup>63</sup> magnetic resonance chemical analysis, which indicated aberrant glutamate levels in depressed individuals as well as evidence of defective NMDA signing in post-mortem tissue preparations.<sup>64</sup> Determining the precise role of salt in depression necessitates additional research because it is a significant excitatory neurotransmitter involved<sup>65</sup> in almost all brain functions (For instance, promising results suggest that the metabotropic salt receptor five is uniquely engaged in severe depressive illness.<sup>66</sup>

### CONCLUSION

The idea of a “unified paradigm of melancholy” is entirely disproven by the vast array of beliefs surrounding depression and the alarmingly low success rates of all existing antidepressant medications. This suggests that depression is a complex condition with diverse causes and clinical presentations. To gain a deeper understanding, extensive research must be conducted on potential biomarkers, including neuroimaging techniques, neuroendocrine testing, and genotyping for individual variations in stress response and medication efficacy. These investigations hold promise for identifying predictors of treatment response and paving the way for personalized healthcare. Ultimately, pinpointing reliable indicators of treatment outcomes could pave the way for tailored treatments designed to suit each patient’s needs. Additionally, it may open up new avenues for testing innovative therapeutic approaches in the pursuit of more effective solutions for managing depressive disorders.



## REFERENCES

1. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *The American Journal of Psychiatry*.2000;157(10):1552-1562.DOI: 10.1176/appi.ajp.157.10.1552
2. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. *The American Journal of Psychiatry*.2006;163(1):115-124. DOI: 10.1176/appi.ajp.163.1.115
3. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. *Archives of general psychiatry*. 1989;46(11):971-983. DOI:10.1001/archpsyc.1989.01810110013002
4. Suryawanshi C, Wagh R. New Amino-Anthracene-9, 10-Dione Derivatives: Synthesis and Pharmacological Evaluation as Powerful Neuroprotective and Antidepressant Agents. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(3):756-761. DOI: 10.25258/ijpqa.14.3.50
5. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447(7145):661-678. DOI:10.1038/nature05911
6. Caspi A, Sugden K, Moffitt TE. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science*. 2003;301(5631):386-389. DOI:10.1126/science.1083968
7. Risch N, Herrell R, Lehner T. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. *Journal of the American Medical Association*. 2009;301(23):2462-2471. DOI:10.1001/jama.2009.878
8. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. *Biological Psychiatry*. 2006;60(2):93-105. DOI: 10.1016/j.biopsych.2005.11.006
9. Young EA. Sex differences and the HPA axis: implications for psychiatric disease. *Journal of Personalized Medicine*.1998;1(1):21-27. DOI: [10.1016/j.arr.2005.03.003](https://doi.org/10.1016/j.arr.2005.03.003)
10. Stroud LR, Salovey P, Epel ES. Sex differences in stress responses: social rejection versus achievement stress. *Biological Psychiatry*. 2002;52(4):318-327.DOI:10.1016/s0006-3223(02)01333-1
11. Belmaker RH, Agam G. Major depressive disorder. *The New England Journal of Medicine*. 2008;358(1):55-68.DOI:10.1056/NEJMra073096
12. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. *Trends in Neurosciences*. 2008;31(9):464-468. DOI:10.1016/j.tins.2008.06.006
13. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. *Psychoneuroendocrinology*. 2008;33(6):693-710. DOI:10.1016/j.psyneuen.2008.03.008
14. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. *The Proceedings of the Association of American Physicians*.1999;111(1):22-34. DOI:10.1046/j.1525-1381.1999.09423.x
15. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. *Journal of Neuroendocrinology*. 2007;19(3):213-226. DOI:10.1111/j.1365-2826.2006.01516.x
16. Mizoguchi K, Ishige A, Aburada M, Tabira T. Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. *Neuroscience*. 2003;119(3):887-897. DOI:10.1016/s0306-4522(03)00105-2
17. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in major depression. *Archives of general psychiatry*.2003;60(1):24-28. DOI:10.1001/archpsyc.60.1.24
18. McGowan PO, Sasaki A, D'Alessio AC. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nature Neuroscience*. 2009;12(3):342-348. DOI:10.1038/nn.2270
19. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *Journal of Psychiatric Research*. 1994;28(4):341-356. DOI:10.1016/0022-3956(94)90017-5
20. Al-Terehi MN, Altamari US, Kadhim AJ, Al-Rrubaei HA. The Combination Between Anti-depressant and Anti-diabetic Therapy Effects in Depressed Patients with Type 2 Diabetic Mellitus. *International Journal of Pharmaceutical Quality Assurance*. 2021;12(4):287-289. DOI: 10.25258/ijpqa.12.4.11
21. Schatzberg AF, Lindley S. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. *The European Journal of Pharmacology*. 2008;583(2-3):358-364. DOI: 10.1016/j.ejphar.2008.01.001
22. Nemeroff CB, Widerlöv E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. *Science*. 1984;226(4680):1342-1344. DOI:10.1126/science.6334362
23. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. *Archives of general psychiatry*. 1988;45(6):577-579. DOI:10.1001/archpsyc.1988.01800300075009
24. Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. *The European Journal of Pharmacology*. 2008;583(2-3):350-357. DOI: 10.1016/j.ejphar.2007.12.032
25. Al Mashhadani ZI, Ali MH, Al-Terehi MN. Correlation Between the Dopamine and ROS Levels in Depression Disorders. *International Journal of Pharmaceutical Quality Assurance*. 2021;12(4):328-330. DOI: 10.25258/ijpqa.12.4.18
26. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. *International Clinical Psychopharmacology*.2006;21(4):227-231. DOI:10.1097/00004850-200607000-00005
27. Nemeroff CB, Heim CM, Thase ME. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100(24):14293-14296. DOI:10.1073/pnas.2336126100
28. Neumeister A, Konstantinidis A, Stastny J. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. *Archives of general psychiatry*.2002;59(7):613-620. DOI:10.1001/archpsyc.59.7.613
29. Neumeister A, Nugent AC, Waldeck T. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. *Archives of general psychiatry*. 2004;61(8):765-773. DOI:10.1001/

- archpsyc.61.8.765
30. Neumeister A, Bain E, Nugent AC. Reduced serotonin type 1A receptor binding in panic disorder. *Journal of Neuroscience*. 2004;24(3):589-591. DOI:10.1523/JNEUROSCI.4921-03.2004
  31. Junnuthula V, Kolimi P, Nyavanandi D, Sampathi S, Vora LK, Dyawanapelly S. Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations. *Pharmaceutics*. 2022 Sep 3;14(9): 1860.https://doi.org/10.3390/pharmaceutics14091860
  32. Zhang X, Gainetdinov RR, Beaulieu JM. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. *Neuron*. 2005;45(1):11-16. DOI:10.1016/j.neuron.2004.12.014
  33. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. *signal transduction knowledge environment*. 2004;2004(225). DOI:10.1126/stke.2252004re5
  34. Jawad MA, Al-Terehi MN, Kadhim AJ. Effect of Antidepressants Medications in Glycemic State of Depression Disorders Patients. *International Journal of Pharmaceutical Quality Assurance*. 2021;12(3):217-219. DOI: 10.25258/ijpqa.12.3.10
  35. Pizzagalli DA, Berretta S, Wooten D. Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder: In Vivo Positron Emission Tomography and Postmortem Evidence. *Journal of the American Medical Association*. 2019;76(8):854-861. DOI:10.1001/jamapsychiatry.2019.0801
  36. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. *American Journal of Psychiatry*. 2004;161(3):564-566. DOI:10.1176/appi.ajp.161.3.564
  37. Meyer JH, Krüger S, Wilson AA. Lower dopamine transporter binding potential in striatum during depression. *NeuroReport*. 2001;12(18):4121-4125. DOI:10.1097/00001756-200112210-00052
  38. Hasler G, Fromm S, Carlson PJ. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. *Archives of general psychiatry*. 2008;65(5):521-531. DOI:10.1001/archpsyc.65.5.521
  39. Mann JJ. The medical management of depression. *New England Journal of Medicine*. 2005;353(17):1819-1834. DOI:10.1056/NEJMra050730
  40. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. *Journal of Clinical Psychiatry*. 2005;66(1):85-93. DOI:10.4088/jcp.v66n0112
  41. Kolimi P, Youssef AA, Narala S, Nyavanandi D, Dudhipala N, Bandari S, Repka MA. Development and characterization of itraconazole non-aqueous creams for the treatment of topical fungal infections. *Journal of Drug Delivery Science and Technology*. 2022 Oct 1;76:103818. DOI:10.1016/j.jddst.2022.103818
  42. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression. *Human Brain Mapping*. 2008;29(6):683-695. DOI:10.1002/hbm.20426
  43. Rajkowska G, Miguel-Hidalgo JJ, Wei J. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biological Psychiatry*. 1999;45(9):1085-1098. DOI:10.1016/s0006-3223(99)00041-4
  44. Price JL, Drevets WC. Neurocircuitry of mood disorders. *Neuropsychopharmacology*. 2010;35(1):192-216. DOI:10.1038/npp.2009.104
  45. Damasio AR, Tranel D, Damasio H. Individuals with sociopathic behavior caused by frontal damage fail to respond autonomically to social stimuli. *Behavioural Brain Research* 1990;41(2):81-94. DOI:10.1016/0166-4328(90)90144-4
  46. Mayberg HS, Lozano AM, Voon V. Deep brain stimulation for treatment-resistant depression. *Neuron*. 2005;45(5):651-660. DOI:10.1016/j.neuron.2005.02.014
  47. Chi KF, Korgaonkar M, Grieve SM. Imaging predictors of remission to anti-depressant medications in major depressive disorder. *Journal of Affective Disorders*. 2015;186:134-144. DOI:10.1016/j.jad.2015.07.002
  48. Kessing LV, Hansen MG, Andersen PK, Angst J. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders -a life-long perspective. *Acta Psychiatrica Scandinavica*. 2004;109(5):339-344. DOI:10.1046/j.1600-0447.2003.00266.x
  49. Hasler G, Fromm S, Alvarez RP, Luckenbaugh DA, Drevets WC, Grillon C. Cerebral blood flow in immediate and sustained anxiety. *Journal of Neuroscience*. 2007;27(23):6313-6319. DOI:10.1523/JNEUROSCI.5369-06.2007
  50. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. *Nature Neuroscience*. 2007;10(9):1089-1093. DOI:10.1038/nrn1971
  51. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. *Archives of general psychiatry*. 2007;64(2):193-200. DOI:10.1001/archpsyc.64.2.193
  52. Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. *Neuropsychopharmacology*. 2007;32(2):471-482. DOI:10.1038/sj.npp.1301234
  53. Eser D, Schüle C, Baghai TC, Romeo E, Rupprecht R. Neuroactive steroids in depression and anxiety disorders: clinical studies. *Neuroendocrinology*. 2006;84(4):244-254. DOI:10.1159/000097879
  54. Duncan WC Jr. Circadian rhythms and the pharmacology of affective illness. *Pharmacology & Therapeutics*. 1996;71(3):253-312. DOI:10.1016/s0163-7258(96)00092-7
  55. Hasler G, Neumeister A, van der Veen JW. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. *Biological Psychiatry*. 2005;58(12):969-973. DOI: 10.1016/j.biopsych.2005.05.017
  56. Zarate CA Jr, Singh JB, Carlson PJ. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of general psychiatry*. 2006;63(8):856-864. DOI:10.1001/archpsyc.63.8.856
  57. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. *Expert Opinion on Therapeutic Targets*. 2005;9(1):153-168. DOI:10.1517/14728222.9.1.153
  58. Deschwandan A, Karolewicz B, Feyissa AM. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. *American Journal of Psychiatry*. 2011;168(7):727-734.



- DOI:10.1176/appi.ajp.2011.09111607
59. Kim JH, Joo YH, Son YD, et al. In vivo metabotropic glutamate receptor 5 availability-associated functional connectivity alterations in drug-naïve young adults with major depression. *European Neuropsychopharmacology*. 2019;29(2):278-290. DOI:10.1016/j.euroneuro.2018.12.001
  60. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. *American Journal of Psychiatry*. 1986;143(1):24-28. DOI:10.1176/ajp.143.1.24
  61. Leventhal AM, Rehm LP. The empirical status of melancholia: implications for psychology. *Clinical Psychology Review*. 2005;25(1):25-44. DOI:10.1016/j.cpr.2004.09.001
  62. Benazzi F, Akiskal H. Irritable-hostile depression: further validation as a bipolar depressive mixed state. *Journal of Affective Disorder*. 2005;84(2-3):197-207. DOI:10.1016/j.jad.2004.07.006
  63. Kim JH, Joo YH, Son YD. In vivo metabotropic glutamate receptor 5 availability-associated functional connectivity alterations in drug-naïve young adults with major depression. *European Neuropsychopharmacology*. 2019;29(2):278-290. DOI:10.1016/j.euroneuro.2018.12.001
  64. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. *Journal of Affective Disorders*. 2005;85(3):245-258. DOI:10.1016/j.jad.2004.12.004
  65. Iuso S, Severo M, Trotta N. Improvements in Treatment Adherence after Family Psychoeducation in Patients Affected by Psychosis: Preliminary Findings. *Journal Of Personalized Medicine*. 2023;13(10):1437. DOI:10.3390/jpm13101437
  66. Vanukuru N.V.L.S.R., Mudunuri GR, Bhimasani P, Malipatel N, Thorat M, Tare H. Pre-clinical Evaluation and In-silico Docking of *Coriandrum sativum* on Stress and Cognitive Deficits in Rodents. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(1):36-44. DOI: 10.25258/ijpqa.14.1.08